IL28432A - Substituted 3-amino-sydnonimines and processes for their manufacture - Google Patents
Substituted 3-amino-sydnonimines and processes for their manufactureInfo
- Publication number
- IL28432A IL28432A IL6728432A IL2843267A IL28432A IL 28432 A IL28432 A IL 28432A IL 6728432 A IL6728432 A IL 6728432A IL 2843267 A IL2843267 A IL 2843267A IL 28432 A IL28432 A IL 28432A
- Authority
- IL
- Israel
- Prior art keywords
- sydnonimine
- amino
- mol
- hydrochloride
- added
- Prior art date
Links
- 238000000034 method Methods 0.000 title description 7
- QVZILVCJQMNOLN-UHFFFAOYSA-N 5-imino-1-oxa-3-azonia-2-azanidacyclopent-3-en-3-amine Chemical class N[N+]1=CC(=N)O[N-]1 QVZILVCJQMNOLN-UHFFFAOYSA-N 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 67
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 239000000203 mixture Substances 0.000 description 28
- 239000000243 solution Substances 0.000 description 24
- 150000001875 compounds Chemical class 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 238000000354 decomposition reaction Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000001816 cooling Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- GSKDBLIBBOYOFU-UHFFFAOYSA-N oxadiazol-5-amine Chemical compound NC1=CN=NO1 GSKDBLIBBOYOFU-UHFFFAOYSA-N 0.000 description 7
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 7
- -1 5-nitrofuryl Chemical group 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 239000012043 crude product Substances 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 150000002832 nitroso derivatives Chemical class 0.000 description 6
- 235000010288 sodium nitrite Nutrition 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000008098 formaldehyde solution Substances 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 235000019759 Maize starch Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Substances CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- YBOQSVRDMSNIOX-UHFFFAOYSA-N 5-imino-n,n-dimethyl-1-oxa-3-azonia-2-azanidacyclopent-3-en-3-amine Chemical compound CN(C)[N+]1=CC(=N)O[N-]1 YBOQSVRDMSNIOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000003884 phenylalkyl group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 239000002026 chloroform extract Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- UPVLRUMEBXYJMQ-UHFFFAOYSA-N 1,1-bis(prop-2-enyl)hydrazine Chemical compound C=CCN(N)CC=C UPVLRUMEBXYJMQ-UHFFFAOYSA-N 0.000 description 1
- ORAMJWCHWLRISI-UHFFFAOYSA-N 1-(5-imino-1-oxa-3-azonia-2-azanidacyclopent-3-en-3-yl)ethanone Chemical compound CC(=O)[N+]1=CC(=N)O[N-]1 ORAMJWCHWLRISI-UHFFFAOYSA-N 0.000 description 1
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
- FTBYHABJPALDSP-UHFFFAOYSA-N 1-benzyl-1-methylhydrazine Chemical compound CN(N)CC1=CC=CC=C1 FTBYHABJPALDSP-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JJMQIJNYXQVIKP-UHFFFAOYSA-N 3-(azepan-1-yl)-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine Chemical compound [N-]1OC(=N)C=[N+]1N1CCCCCC1 JJMQIJNYXQVIKP-UHFFFAOYSA-N 0.000 description 1
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 1
- MVFWHQWYMIVZJF-UHFFFAOYSA-N 3-piperidin-1-yl-1-oxa-3-azonia-2-azanidacyclopent-3-en-5-imine;hydrochloride Chemical compound Cl.[N-]1OC(=N)C=[N+]1N1CCCCC1 MVFWHQWYMIVZJF-UHFFFAOYSA-N 0.000 description 1
- OLEFNFXYGGTROA-UHFFFAOYSA-N 5-nitrofuran-2-carbonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)O1 OLEFNFXYGGTROA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- FHKRFUHAZOWBHF-UHFFFAOYSA-N CC1=CC=CC(CN[N+]([N-]O2)=CC2=N)=C1 Chemical compound CC1=CC=CC(CN[N+]([N-]O2)=CC2=N)=C1 FHKRFUHAZOWBHF-UHFFFAOYSA-N 0.000 description 1
- YDRXPASRJIFKDB-UHFFFAOYSA-N C[N+]=1[N-]OC(C=1N1CCNCC1)=N Chemical compound C[N+]=1[N-]OC(C=1N1CCNCC1)=N YDRXPASRJIFKDB-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- BQIKRTGTPBOIMK-UHFFFAOYSA-N [O]C[O] Chemical compound [O]C[O] BQIKRTGTPBOIMK-UHFFFAOYSA-N 0.000 description 1
- GANYMSDHMBJFIL-UHFFFAOYSA-N acetonitrile;ethoxyethane Chemical compound CC#N.CCOCC GANYMSDHMBJFIL-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- DFNYGALUNNFWKJ-UHFFFAOYSA-N aminoacetonitrile Chemical compound NCC#N DFNYGALUNNFWKJ-UHFFFAOYSA-N 0.000 description 1
- BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NALBLJLOBICXRH-UHFFFAOYSA-N dinitrogen monohydride Chemical group N=[N] NALBLJLOBICXRH-UHFFFAOYSA-N 0.000 description 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- IFXAHRLRJPMJMP-UHFFFAOYSA-N ethyl 5-imino-1-oxa-3-azonia-2-azanidacyclopent-3-ene-3-carboxylate Chemical compound CCOC(=O)[N+]1=CC(=N)O[N-]1 IFXAHRLRJPMJMP-UHFFFAOYSA-N 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229940043351 ethyl-p-hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Substances OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- KRIOVPPHQSLHCZ-UHFFFAOYSA-N phenyl propionaldehyde Natural products CCC(=O)C1=CC=CC=C1 KRIOVPPHQSLHCZ-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012261 resinous substance Substances 0.000 description 1
- 230000000894 saliuretic effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/04—1,2,3-Oxadiazoles; Hydrogenated 1,2,3-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
28432/3 The present invention relates tb .new substituted 3-amino-sydnonimines having valuable pharmacological properties.
According to the present invention we provide compounds of the general formula: .' , ■ , wherein ^ and:R2, which may be identical or different ,' represent:; alkyl, mono- or polyhaloalkyl^ alkenyl, · alkynyl or. phenylalkyl groups, (which latter groups may be substituted in the phenyl ring with one or more halogen atoms or alkyl radicals a or methylenedioxy radical) or a piperidinylmethyl radical or R1 .' and R^, together with the. ad jacent nitrogen atom, represent a heterocyclic ring system which may contain one or more further hetero atoms and may be substituted by at least, one . lower alkyl, carobylic acyl or phenyl group; represents hydrogen, or an alkyl or phenylalkyl group; ^ represents hydrogen or the grou R^CO- where R,- represents an alkyl, cycloalkyl or alkoxy radical or .a phenyl radical which may be. substituted with chlorine or methyl, or a phenylalkyl, 5-nitrofuryl. or. pyridyl radical; and . acid addition salts thereof, for example, hydrohalides , hydrosulphates and hydronitrates In the case where salts of formula 1 are to he used directly as medicines, such salts must of course he non-toxic acid addition salts "by which term we mean those salts, the anionic moieties of which are physiologically compatible in the dosages at which the salts are administered. Non toxic salts may be formed from other salts by conventional ion-exchange methods.
According to a further feature of the invention, we provide a process for the preparation of compounds of formula I (as hereinbefore defined) which comprises reacting a compound of formula Εη NO CN (wherein R^, R2 and R^ are as hereinbefore defined) with an agent serving to effect the cyclisation of said nitroso compound to form a compound of formula I in which R^ = H, which compound is, if desired, reacted with an acylating agent serving to introduce the R5CO- group (where R^ is. as defined herein) at the 6-position.
The cyclisation of a compound of formula II according to the invention can be effected with the aid of conventional condensing agents, such as strong The reaction can be carried out either in the presence or absence of solvents. Methanol, ethanol, acetone, chloroform, tetrahydrofuran and water are par-r ticularly preferred for use as solvents. The reaction can be effected at moderately elevated temperatures, ambient temperature or under cooling.
To obtain compounds of formula I which are acylated at the 6 nitrogen atom, the compounds of general formula I, wherein R^ represents hydrogen, obtained according to the above-described process, may be acylated at the imino nitrogen atom by any convenient method, for example, by treatment with the corresponding acid halide or anhydride, such as acetic anhydride, benzoyl chloride or nicotinoyl chloride, or by reaction with the corresponding halogeno-formic acid ester, for example, methyl or ethyl chloro-formate. This reaction is preferably carried out in the presence of an acid-acceptor, for example an organic or inorganic base, such as pyridine, or an alkali metal carbonate or acetate, if desired, in the presence of a solvent.
The compounds of formula I in the free-base may often be unstable and are hence preferably isolated in the form of an acid addition salt thereof. Such compounds in which R^ is a group R^CO- may however be sufficiently stable to be isolated and used in the free-base form. Acid addition salts may be formed with inorganic or organic acids.
Preferred inorganic acids for the preparation of The following compounds may for example be used as starting materials: N-nitroso-(dimethylamino)-ramino-acetonitrile ; N-nitroso-(morpholino)-amino-acetonitrile; N-nitroso-(metliyl-plienylethylamino)~amino-aGetonitrile; N-nitroso-(methyl-2-piperidinylmethylamino)-amino- acetonitrile; N-nitroso-met^l-a-methylbenzylamino)-amino-acetonitrile ; N-nitroso-(2-phenylpiperidino)-amino-acetonitrile ; N-nitroso-(dibenzylamino) amino-acetonitrile ; N-nitroso-(methyl-propargylamino)-amino-acetonitrile; N-nitroso-(methyl-benzylamino)-amino-acetonitrile; N-nitroso-(diallylamino)-amino-acetonitrile ; N-nitroso-(hexamethyleneimino)-amino-acetonitrile; N-nitroso-C^-methylpiperazinyl-l1)-amino-acetonitrile; N-nitroso-(l,2,3, -tetrahydroisoquinolinyl)-amino- acetonitrile; N-nitroso-(piperidino)-amino-acetonitrile ; N-nitroso-(diallylamino)-a-pbenylethyl-amino-acetonitrile; N-nitroso-(diallylamino)-a-methyl-amino-acetonitrile; N-nitroso-(diallylamino)-a-ethyl-amino-acetonitrile; N-nitroso-(pyrrolidino)-amino-acetonitrile , As mentioned above, the substituted 3-amino-sydnonimines and their acid addition salts according to the invention have valuable pharmacological properties. The compounds according to the invention lower the blood pressure for particularly long periods even when administered in small doses and also display an action on the invention, we provide pharmaceutical compositions comprising, as active ingredient, at least one compound of formula I (as hereinbefore defined) or a non-toxic acid addition salt thereof in association with a pharmaceutical carrier or excipient.
The compositions may be presented in a form suitable for enteral, e.g. oral, or parenteral administration. Thus, for example, compositions for oral administration may be solid or liquid and may take the form of granules, tablets, dragees, pills, coated tablets, capsules, syrups, emulsions, solutions, suspensions or drops, such compositions comprising carriers or excipients conventionally used in the pharmaceutical art.
The compositions may thus include fillers, extenders, binders, disintegrating agents, lubricants, thickeners, diluents, solvents, solubility-promoters, agents for achieving a depot-effect, emulsifiers or buffer substances. For example, suitable tabletting excipients include lactose, potato and soluble starches and magnesium stearate.
For parenteral administration, the carrier may be a sterile, parenterally acceptable liquid such as sterile water, or a parenterally acceptable oil e.g. arachis oil, contained in ampoules or multi-dose flasks. Compositions for rectal administration may take the form of suppositories, the carrier comprising a suppository base. tablets, capsules and ampoules are examples of suitable dosage unit forms. Each dosage unit preferably contains 10 to 100 mg, and especially 20 to 50 mg, of active ingredient.
The compositions according to the invention may, if desired, also contain a further therapeutic compound, e.g. a compound having a saluretic activity.
The following examples Illustrate the invention.
Example 1 3-Piperidino«-sydnonimine To a mixture consisting of 95 g (0.95 moi) N-amino-piperidine and 100 ml water, 80 ml of concentrated hydrochloric acid were added at 10°0 slowly with stirring, so that the pH was approximately neutral. The mixture was then cooled to 5°C in the ice bath and in the course of 30 minutes a solution of 61.5 g (0.95 mol) potassium cyanide in 130 ml water was added thereto. The temperature was maintained at 10°C and in the course of further 30 minutes 7I .5 ml of a 40% formaldehyde solution (0.95 mol) were added. The mixture was stirred for one hour, then brought to room temperature and stirred for another hour. The mixture was then again cooled, to 5°C and 40 ml of concentrated hydrochloric acid and a solution of 69 g (1 mol) sodium nitrite in 140 ml of water were added. The pH of the solution was maintained at an acid value by gradual addition of 40 ml hydrochloric acid. .
The nitroso-derivative thus formed was extracted with chloroform; the crude yield was 160 g. The crude product was then gradually introduced while stirring and cooling into one litre of methanolic hydrochloric acid. was effected with chloroform containing 20% methanol, to yield 106,2 g (53% of theory) of 3-piperidino-sydnonimine hydrochloride. After recrystallization from methanol/ether , the compound had a melting point of 162-163°C (with decomposition).
Example 2 3-(1«2 , ,4— etrahydroisoquinolinyl)-sydnonimine 9.2 g (0.05 mol) of N-amino-l,2, 3, -tetrahydro-isoquinoline hydrochloride and 75 ml of water were cooled to 5°C in an ice hath, A solution of 3.5 g (0.05 mol) potassium cyanide in 7.0 ml water was then added to this mixture in the course of 15 minutes,. I the course of a further 15 minutes, 3.8 ml of a 40% formaldehyde solution (0.05 mol) were added while stirring, the mixture stirred for one hour, brought to room temperature and stirred for another hour. The mixture was then again cooled to 5°C and sufficient N hydrochloric acid added to obtain a pH of 2. 3.83 g (0, 05 mol) sodium nitrite in 7. ml water were added, and the pH of the solution was kept low by gradual addition of about 20 ml 2N hydrochloric acid.
The nitroso-derivative thus obtained was extracted with chloroform yielding 11 g of crude product. The latter was slowly introduced while stirring and cooling into 120 ml methanolic hydrochloric acid, the resulting solution was evaporated in vacuo at 30°C, and the residue chromatographed on silica. Elution was effected with chloroform containing 10% methanol. There methanol/ether , melted at 155°C (with decomposition).
Example 3 1 1 3-(4- -Methyl-piperazinyl-1 )-sydnonimine To a mixture consisting of 10 g (0.066 mol) 1-amino- -methylpiperazine-hydrochloride and 30 ml water, cooled to 5°C in an ice "bath, a solution of 4-.4- g potassium cyanide (0.066 mol) in 25 ml of water was added while stirring. In the course of 30 minutes while 5 ml of a 4-0% formaldehyde solution (0.066 mol) were then introduced at the same temperature, the mixture stirred for one hour, the solution brought to room temperature and stirred for another hour. The mixture was then again cooled to 5°C» and 3.5 ml concentrated hydrochloric acid and subsequently 4.6 g (0.066 mol) sodium nitrite dissolved in 75 ml water were added dropwise. The pH-value of the solution was kept low by the gradual addition of 3.5 ml concentrated hydrochloric acid.
The nitroso-compound was extracted with chloroform and the 13.8 g crude product obtained were introduced slowly while cooling into 70 ml methanolic hydrochloric acid. The resulting 3-(4- -methyl-piperazinyl-1 )-sydnonimine hydrochloride crystallized spontaneously from the solution. The crystal-containing solution was evaporated to dryness and recrystallized from ethanol.
There were obtained in this manner 9.9 g. (59% of theory) of end-product, melting at 187 - 188°C (with decomposition) Example 4- 3-Hexamethylene-imino-sydnonimine then cooled to 5°C in an ice hath and a solution of 66 g (1 mol) potassium cyanide in 150 ml water added over 30 minutes. In. the course of a further JO" minutes-, 75 ml of a 40% formaldehyde solution (1 mol) were added, the mixture stirred for one hour and brought to room temperature in the course of another hour. After renewed cooling to 5°C, 5 ml concentrated hydrochloric acid and subsequently 69 g (1 mol) sodium nitrite in 140 ml water were slowly added. The pH of the solution was maintained in the acid range by gradual addition of 45 ml concentrated hydrochloric acid.
The nitroso-derivative was extracted with chloroform and the resulting, 172 g crude product were introduced slowly while stirring into one litre methanolic hydrochloric acid. The resulting solution was concentrated in vacuo at 30°0 and chromatographed on silica. After elution with chloroform containing 10% methanol, 113.8 g (52% of theory) of 3-hexamethylene-imino-sydnonimine hydrochloride were obtained, which, after recrystalliza-tion from methanol/ether had a melting point of 153 -154°C (decomposition).
Example 5 3-Diallylamino-sydnonimine To 72 g (0.64 mol) 1,1-diallylhydrazine suspended in 150 ml water, there were added slowly at 10°C while stirring, 45 ml pf concentrated hydrochloric acid. The mixture was cooled to 5°C in an ice bath and a solution of 3 g (0.64 mol) potassium cyanide in 90 ml water added in the course of 0 minutes. The tem erature was maintained again cooled to 5°C, and 50 ml of 4—N hydrochloric acid added in the course of 50 minutes. A solution of 4-8 g sodium nitrite in 100 ml water (0.07 mol) was then added and the pH-value was kept low by the gradual addition of 1 0 ml of 4-N hydrochloric acid. The mixture was stirred for one hour at a temperature of 5 - 10°C, brought to room temperature and extracted three times with ohloro-form. The chloroform extracts were dried over sodium sulphate, filtered and brought to dryness in vacuo. 122 g of crude product were obtained, which were dissolved in 180 ml of methanol and added slowly to 2 litres methanolic hydrochloric acid. The resulting solution was concentrated in vacuo at 50°C and chromatographed on silica. After elution with chloroform containing 10% methanol, there were obtained 78 g (56% of theory) of 3-diallylamino-sydnonimine hydrochloride, which, after recrystallization from methanol/ether had an Hp. of 94— 96°C (decomposition).
Example 6 3-Methyl-benzylamino-sydnonimine 60 ml of concentrated hydrochloric acid were added with stirring and cooling to a mixture of 87 g (0.64-mol) 1-benzyl-l-methylhydrazine suspended in 200 ml water. The mixture was cooled to 5°C in an ice bath and a solution of 42 g (0.64 mol) potassium cyanide in 90 ml water added in the course of 30 minutes. Within a further 0 minutes, at the same temperature, 50 ml (0.64- mol) of a 4-0% formaldehyde solution were added, Example 18 -Diallylamino-4-phenylethyl-sydnonimine To 56.3 g (0.05 mol)l,l-diallyl-hydrazine there were added with cooling 150 ml water and 20 ml concentrated hydrochloric acid. The mixture was cooled to 5°C in an ice bath and a solution of 52. 5 g (0.5 mol) potassium cyanide in 100 ml water was added thereto in the course of 30 minutes, followed "by the addition, in the course of another hour, of 67.1 g ( 0.5 mol) phenylpropionaldehyde . The mixture was then stirred for one hour, brought to room temperature and stirred for another hour. It was then again cooled to 5°C> and 24 ml concentrated hydrochloric acid added and then 3 , 5 g (0. 5 mol) sodium nitrite in 100 ml water.
The nitroso-derivative thus formed was extracted with chloroform, to yield 136 g of crude product, which was added slowly dropwise to 1 , 5 litres methanolic hydrochloric acid while stirring and cooling. The resulting solution was concentrated in vacuo at 30°C and the residue chromatographed on silica. 115g (74·% of the theory) of 3-diallylamino-4-phenylethyl-sydnonimine hydrochloride were obtained which, after recrystallization from isopropanol/ether, had a melting temperature of 113-114°C (decomposition).
The following further compounds were obtained by the method described in Example 18: Yield " '· Example n _ _ _ _ ,, _ A (% xP« No. G o m.p-o u n d theory) °G 19 3-diallylamino- -methyl- 71 HO - 112 d com Example 21 g 3-Piperidino-H -acetyl-sydnonimine To a mixture of 25 ml acetic anhydride and 5 ml pyridine 2„ 5 S (0.0125 mol) 5-piperidino-sydnonimine hydrochloride were added. The mixture was heated to 30°C until complete dissolution, and was then left to stand for 3 hours, at room temperature and then for two days at 5°C. The crystals which have separated by the end of this period were filtered off. The mother liquor was evaporated to dryness and the remaining resinous substance was crystallized'from methanol/ether. The two crystalline fractions obtained were identical and constituted a yield of 1.96 g ( 33%, calculated on the amount of hydrazine hydrochloride employed) of 3-piperidino-N^-acetyl-sydnonimine, melting at 175°C (decomposition).
Example 22 3-Dimethylamino-N 6-ethoxycarbonyl-sydnonimine hydrochloride A mixture consisting of 16.5 g (0.1 mol) of 3-dimethyl-amino-sydnonimine hydrochloride and 200 ml pyridine was cooled to -10°C and was admixed with 16.5 g (0.10 mol) of ethyl chloroformate added drop-wise. The temperature was then allowed to rise firstly to 5°C and then to room temperature, and the mixture was stirred at this temperature for 3 hours. 500 ml of water were then added and the solution was extracted with chloroform. The chloroform-extracts a o to and the crystals then separating were filtered off.
There were obtained in this manner 16 g (34%) of 3-dimethy1amino-N^-ethoxycarbony1-sydnonimine hydro-chloride, melting at 155°C (decomposition).
Example 23 g 3-Dimethylamino-N -3-nitrofuroyl-sydnonimine 150 ml pyridine were admixed with 12 g (0.07 mol) 3-dimethylamino-sydnonimine hydrochloride and 17.5 g (0.1 mol) 5-nitrofuroyl chloride. The mixture was allowed to stand at room temperature for 3.5 hours, then overnight at 0°C, The excess of acid chloride was then destroyed by addin 25 ml water and the solution was distributed between 100 ml water and 200 ml chloroform. The two layers were then separated and the aqueous phase was extracted four times with 150 ml portions of chloroform. The combined chloroform solutions were dried and the solvent was removed in vacuo. The remaining resin was crystallised from acetonitrile/ether. There were obtained in this manner 12.2 g (43% of theory) of 3- 6 dimethylamino-N -5-nitrofuroyl-sydnonimine , with an Mp, of 218 - 219°C (decomposition), after recrystallization from acetonitrile-ether.
The following further compounds were obtained by the process according to the invention: Example Yield No. C o m p o u n d theory) 24 3-diallylamino-N6-acetyl- 36 108 - 109 sydnonimine hydrochloride (decomp.) 3-hexamethyleneimino-N6-benzoyl- 32 149 - 150 s dnonimine h drochloride decom Yisld Example No. C o m p o u n d theory) 27 3-dimethylamino-N -phenylpro- 35 153 - 154 pionyl-sydnonimine (decomp. ) hydrochloride 28 3-piperidino-N -ethoxycarbonyl- 3 139 - 141 sydnonimine hydrochloride (decomp. ) 29 3-diallylamino-4-ethyl-N6- 7 95 - 96 ethoxy-carbonyl-sydnonimine (decomp. ) hydrochloride 6 3-dimethylamino-rN -acetyl- 54 174 sydnonimine hydrochloride (decomp. ) g 31 3-plperidino-N -acetyl-sydnoni- 31 96 - 97 mine methiodide (decomp. ) 32 3-(1-acetylhomopiperazino)-N^- 31 179 ' acetyl-sydnonimine - hydrochloride (decomp. ) ✓ 33 6 3-?dimethylamino-N -benzoyl- 60 178 sydnonimine hydrochloride (decomp. ) 6 34- 3-dimethylamino-N -o-chloro- 67 16 - 168 benzpyl-sydnonimine hydrochloride (decomp. ) g .
Ks 35 3-dimethylamino-N -p-chloroben- 62 184 - 185 zoyl-sydnonimine hydrochloride (decomp. ) 3-dimethylamino-N^-o-methylben- 63 160 - 162 zoyl-sydnonimine hydrochloride (decomp. ) ^37 3-dimethylamino-N -cyclohexyl- 59 187 carbonyl-sydnonimine (decomp. ) hydrochloride .g 638 3-dimethylamino-N -cyclopropyl- 48 181 - 184 carbonyl-sydnonimine (decomp. ) hydrochloride g L/39 3-dimethylamino-N -nicotinoyl- 57 198 - 199 sydnonimine hydrochloride (decomp. ) ^ 0 3-dimethylamino-N -tert . -butyl- 49 168 acetyl-sydnonimine (decomp. ) hydrochloride - g 1 3-morpholino-N -cyclohexylcarbo- 61 187 nyl-sydnonimine hydrochloride (decomp. ) Example 42 Dragees (a) 3-(l,2,3,4-Tetrahydro-isoquinolinyl)- 50 mg sydnonimine hydrochloride Lactose 65 m Maize starch 90 mg Secondary calcium phosphate 35 m Soluble starch 3 mg Magnesium stearate 3 mg Colloidal silica 4 mg 250 mg (b ) 3-Dimethylamino-sydnonimine hydrochloride . ·■ · 30 mg Lactose 55 mg Maize starch - 75 mg Secondary calcium phosphate 30 mg Soluble starch 3 mg Magnesium stearate 3 mg Colloidal silica 4 mg 200 mg Example 43 Tablets 3-N-methyl-piperazino-sydnonimine ;35 m hydrochloride Lactose 60 mg Maize starch 35 mg Soluble starch 4 mg Magnesium stearate 1 mg 135 mg Example 44 Drops (20.0 mg in 1 ml - 20 drops) 3-Hexamethyleneimino-sydnonimine 2.00 g hydrochloride Methyl-p-hydrqxy-benzoate 0.07 S Ethyl-p-hydroxy-benzoate 0.03 g Ethanol, 96% 20 ml Demineralised water q.s.p. 100 ml Example $ Ampoules 6 3-piperidino-N -acetyl- 20.0 mg sydnonimine hydrochloride •Sodium chloride 18.0 mg Distilled water q.s.p. 2 ml Example 46 Capsules The contents of each capsule are composed of:: 3-dimethylamino-N -(5-nitrofuroyl)- sydnonimine 25 mg Maize starch 175 mg
Claims (2)
1.
2. 3-Dimethylamino-N -(5-nitrofuroyl)-sy
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEB0088408 | 1966-08-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL28432A true IL28432A (en) | 1972-01-27 |
Family
ID=6984280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL6728432A IL28432A (en) | 1966-08-09 | 1967-08-01 | Substituted 3-amino-sydnonimines and processes for their manufacture |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS537433B1 (en) |
| BE (1) | BE702448A (en) |
| BG (1) | BG15571A3 (en) |
| CA (1) | CA925083A (en) |
| CH (1) | CH507277A (en) |
| DE (1) | DE1670127A1 (en) |
| DK (1) | DK126594B (en) |
| ES (1) | ES343818A1 (en) |
| FI (1) | FI49420C (en) |
| FR (2) | FR1551013A (en) |
| GB (1) | GB1198283A (en) |
| IL (1) | IL28432A (en) |
| NL (1) | NL153195B (en) |
| PH (1) | PH10178A (en) |
| SE (1) | SE343304B (en) |
| YU (1) | YU34691B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2930736A1 (en) * | 1979-07-28 | 1981-02-12 | Cassella Ag | PHARMACOLOGICALLY ACTIVE, SUBSTITUTED 3-AMINO-SYDNONIMINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE |
| DE3837327A1 (en) * | 1988-11-03 | 1990-05-10 | Cassella Ag | SUBSTITUTED 3-AMINO-DYNONOMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| DE3921460A1 (en) * | 1989-06-30 | 1991-01-03 | Cassella Ag | SUBSTITUTED 3-AMINO-DYNONOMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| DE3921796A1 (en) * | 1989-07-03 | 1991-01-17 | Cassella Ag | SUBSTITUTED 3-AMINO-DYNONOMINES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| DE4025604A1 (en) * | 1990-08-13 | 1992-02-20 | Cassella Ag | 3-DICYCLOHEXYLAMINO-SYDNONIMINE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| DE4028679A1 (en) * | 1990-09-10 | 1992-03-19 | Cassella Ag | SUBSTITUTED 3-AMINOSYDNONIMINE, METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO1993018767A1 (en) * | 1992-03-24 | 1993-09-30 | Cassella Aktiengesellschaft | Use of sydnonimines to treat erectile dysfunction |
| DE4337335A1 (en) * | 1993-11-02 | 1995-05-04 | Cassella Ag | Process for the preparation of Sydnoniminium hydrogen sulfate |
-
1966
- 1966-08-09 DE DE19661670127 patent/DE1670127A1/en not_active Ceased
-
1967
- 1967-07-28 SE SE10943/67A patent/SE343304B/en unknown
- 1967-07-31 GB GB35049/67A patent/GB1198283A/en not_active Expired
- 1967-08-01 IL IL6728432A patent/IL28432A/en unknown
- 1967-08-03 CH CH1092567A patent/CH507277A/en not_active IP Right Cessation
- 1967-08-03 CA CA996993A patent/CA925083A/en not_active Expired
- 1967-08-04 ES ES343818A patent/ES343818A1/en not_active Expired
- 1967-08-05 BG BG008440A patent/BG15571A3/en unknown
- 1967-08-07 FI FI672132A patent/FI49420C/en active
- 1967-08-08 YU YU1565/67A patent/YU34691B/en unknown
- 1967-08-08 DK DK404167AA patent/DK126594B/en not_active IP Right Cessation
- 1967-08-08 BE BE702448D patent/BE702448A/xx not_active IP Right Cessation
- 1967-08-09 NL NL676710945A patent/NL153195B/en not_active IP Right Cessation
- 1967-08-09 JP JP5076167A patent/JPS537433B1/ja active Pending
- 1967-08-09 FR FR1551013D patent/FR1551013A/fr not_active Expired
- 1967-11-09 FR FR127616A patent/FR8428M/fr not_active Expired
-
1972
- 1972-08-21 PH PH13823A patent/PH10178A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CH507277A (en) | 1971-05-15 |
| FR8428M (en) | 1971-07-08 |
| FR1551013A (en) | 1968-12-27 |
| NL6710945A (en) | 1968-02-12 |
| FI49420B (en) | 1975-02-28 |
| PH10178A (en) | 1976-09-16 |
| YU156567A (en) | 1979-07-10 |
| DE1670127A1 (en) | 1970-12-03 |
| DK126594B (en) | 1973-07-30 |
| ES343818A1 (en) | 1968-12-01 |
| YU34691B (en) | 1979-12-31 |
| SE343304B (en) | 1972-03-06 |
| CA925083A (en) | 1973-04-24 |
| BE702448A (en) | 1968-02-08 |
| FI49420C (en) | 1975-06-10 |
| NL153195B (en) | 1977-05-16 |
| GB1198283A (en) | 1970-07-08 |
| JPS537433B1 (en) | 1978-03-17 |
| BG15571A3 (en) | 1976-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3687965A (en) | Novel 5-(n-substituted aminomethyl)-2-oxazolidinones and their process of preparation | |
| KR900007780B1 (en) | Method for preparing condensed pyrrolidone derivatives | |
| US4855298A (en) | 6-Halo-1,2,3,4-tetrahydroquinazoline-4-spiro-4-imidazolidine-2,2'5'-triones useful for the treatment and prophylaxis of diabetic complications | |
| US3491093A (en) | Derivatives of 5 aminomethyl-4,5,6,7-tetrahydro-4-oxoindoles | |
| US4904676A (en) | Amino-oxazole compounds having dopaminergic activity | |
| GB2097387A (en) | 3,4-dihydro-5h-2,3-benzodiazepine derivatives | |
| CS248035B2 (en) | Production method of the(4(oxo-4h)1(-benzopyran-8-yl)carboxyle acides | |
| US5002949A (en) | 5-substituted-6-aminopyrimidine derivatives | |
| IL28432A (en) | Substituted 3-amino-sydnonimines and processes for their manufacture | |
| GB2088373A (en) | Dibenzazepine derivatives and pharmaceutical compositions containing them | |
| US4153629A (en) | 9,10-Dihydro-9,10-methanoanthracene N-oxide | |
| US4213985A (en) | Novel 5,11-dihydro-6H-pyrido-[2,3-b][1,4]-benzodiazepine-6-ones | |
| US4064244A (en) | Organic compounds | |
| US4256886A (en) | Process for the preparation of oxadiazolopyrimidine derivatives | |
| US3903164A (en) | Pharmacodynamically active amino alkyloxim ethers | |
| US4221793A (en) | N,N'-Disubstituted piperazine derivative | |
| US3980652A (en) | 2-(4-Methyl-piperazino)-3 or 5 cyano pyridine | |
| US3642779A (en) | Indolo(1 2-d)(1 4)benzodiazepin-6-ones | |
| US3836658A (en) | Tri-substituted imidazoles in the treatment of gout | |
| US3694450A (en) | 2-substituted-4,5,6,7-tetrahydrobenzothiazole-4-carboxylic acids and their alkyl esters | |
| PL69663B1 (en) | ||
| US4105777A (en) | Indoles | |
| US4112092A (en) | 1-Naphthylmethyl-4-(thiazolyl-2)-piperazines | |
| US3426017A (en) | Sulfonylurea compounds | |
| US3822267A (en) | 1 substituted 4 piperazino cycloalkylthiazoles |